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Abstract
Objectives: No longitudinal studies have examined how iron measures change over menopause. Our objectives
were to examine iron measures in individual women at premenopause and at postmenopause and, secondarily,
to determine if any changes contributed to insulin resistance.
Methods: In a subset of participants (n = 70) in a longitudinal study of menopause, we measured ferritin,
transferrin, and soluble transferrin receptor (sTfR) once in the premenopause and once in the postmenopause.
We also examined associations between menopausal status and change in iron markers after adjustment for age
at menopause, race/ethnicity, and waist circumference. In linear regression models, we examined associations
between premenopause iron measures and changes in iron markers over menopause with homeostasis model
assessment of insulin resistance (HOMA-IR) changes over menopause, before and after adjustment for age at
menopause, race/ethnicity, changes in waist circumference, C-reactive protein (CRP), and sex hormone-binding
globulin (SHBG) levels.
Results: Women had lower ferritin ( p < 0.01), higher sTfR:ferritin levels ( p < 0.01), lower HOMA-IR ( p = 0.022), and
lower glucose ( p = 0.05) in premenopause compared to postmenopause. After adjustment, lower premenopausal
iron levels (sTfR:ferritin levels b = 11.0, 95% confidence interval [CI] 0.017-22.0) and larger increases in iron over
menopause (changes in sTfR:ferritin b = 13.6, 95% CI 0.93-26.3) were associated with larger increases in HOMA-IR.
Conclusions: From premenopause to postmenopause, women on average have increases in measures of iron
stores. Women who had the greatest changes in iron over menopause (lower measures of premenopausal iron
and greater increases in iron measures over the menopause) had the strongest associations between changes in
iron and changes in insulin resistance.
Introduction
Menopause, traditionally defined as cessation ofmenstrual bleeding, is assumed to lead to an increase in
iron stores over the menopausal transition. However, studies
examining iron measures by menopausal status or age have
been cross-sectional,1–3 and to date, no longitudinal studies
have examined whether menopause is actually associated
with an increase in iron measures.
As women undergo the menopausal transition, they can
experience increases in insulin resistance and other cardio-
vascular risk factors that are not fully explained by changes in
adiposity or sex hormones.4 Iron, a dietary micronutrient and
strong pro-oxidant, catalyzes reactions that cause increased
oxidative stress, a risk factor for insulin resistance.5 Therefore,
an increase in measures of iron over menopause could po-
tentially contribute to women’s increasing insulin resistance
over menopause.
Several markers can represent iron stores. Ferritin, the
primary cellular storage protein for iron, is also an acute-
phase reactant and, thus, may overestimate iron stores in in-
flammatory states.6 Transferrin levels are typically used for
diagnosis of iron overload rather than iron deficiency.7 Serum
levels of soluble transferrin receptor (sTfR) reflect transferrin
receptor not bound to transferrin, with low levels of sTfR
reflecting higher levels of receptor saturation with iron and
lower erythropoiesis.6 As sTfR is increased in iron deficiency
anemia, and ferritin is low in iron deficiency anemia and el-
evated in anemia of chronic disease, the sTfR:ferritin ratio can
be useful for further distinguishing women with elevated
ferritin levels due to lack of iron as opposed to the inflam-
mation associated with chronic disease.6
The Study of Women’s Health Across the Nation (SWAN)
was designed to characterize biologic and sociologic changes
that occur during and after menopause.4 We measured sev-
eral iron markers premenopause and postmenopause in order
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to ascertain (1) if measures of iron increase from pre-
menopause to postmenopause within women longitudinally,
(2) if insulin resistance and glucose increase from pre-
menopause to postmenopause within women longitudinally,
and (3) if premenopausal measures of iron and changes in
measures of iron over menopause are associated with changes
in insulin resistance and glucose over menopause, apart
from other factors associated with insulin resistance, includ-




SWAN is a multisite, longitudinal cohort study of
community-based groups of women.4,10,11 Eligibility criteria
for entry into the SWAN longitudinal cohort were age of
42–52 years, intact uterus and at least one ovary, no current
use of estrogens or other medications known to affect ovarian
function, and at least one menstrual period in the 3 months
before screening. Participants were enrolled at one of the
seven clinic sites, one of which was located in the Detroit area.
This report is based on data from Michigan SWAN site
women.4 SWAN is approved by each local Institutional
Review Board (IRB), and the reported study was approved by
the University of Michigan IRB.
For the purposes of this report, inclusion criteria were
natural menopause as opposed to menopause due to hys-
terectomy or oophorectomy and known date of final men-
strual period. The sample size of 70 participants was based
on estimates of the differences in ferritin observed in cross-
sectional studies between premenopausal and postmeno-
pausal women.2,3 Women were defined as postmenopausal
if they had no menses for ‡ 12 months. We excluded women
who were using estrogen or progestin therapy at the pre-
menopausal or postmenopausal visit and who had diabetes
by self-report at any examination, as changes in insulin re-
sistance and glucose in this population might be affected by
subsequent medication use and behavior modification.
Women were selected at random and were of similar age,
race/ethnicity, and anthropometric size compared to Mi-
chigan SWAN women without diabetes who had under-
gone natural menopause.
Data collection
SWAN annually collects survey data regarding menstrual
status and medical and surgical history from questionnaires,
as well as examination data for anthropometrics. Phlebotomy
was performed in the morning after an overnight fast and
blood was refrigerated 1–2 hours after phlebotomy; after
centrifugation, the serum was aliquoted and frozen. Serum
was stored at - 70C. Insulin was measured in serum by solid
phase radioimmunoassay (Coat-A-Count, Diagnostics Pro-
duct Corp., Los Angeles, CA), and glucose was measured
using a hexokinase-coupled reaction (Roche Molecular Bio-
chemicals Diagnostics, Indianapolis, IN). Insulin resistance
was estimated using homeostasis model assessment of insulin
resistance (HOMA-IR), defined as:
(Fasting insulin · [fasting glucose=18:01])=22:5)12
High-sensitivity C-reactive protein (CRP) was quantitated
using an ultrasensitive rate immunonephrelometric method
(hs-CRP, Dade-Behring, Marburg, Germany). SHBG was a
de novo two-site chemiluminescent assay, with intra-assay
coefficients of 9.9% and 6.1%.
Michigan-specific archival specimens were used for mea-
surement of iron markers in the Rifai Laboratory (Boston,
MA).13 Ferritin was measured by a particle-enhanced im-
munoturbidometric assay (Hitachi 917 analyzer (Roche Di-
agnostics) and Kamiya Biomedical reagents, Seattle, WA). The
day-to-day variability of ferritin at the concentrations of
37.9 ng/mL and 261 ng/mL were 2.5% and 2.6%, respec-
tively. sTfR was measured by a particle-enhanced im-
munoturbidometric assay using the Hitachi 917 analyzer and
Roche Diagnostics reagents. The day-to-day variability of
sTfR at concentrations of 2.25 mg/L and 7.00 mg/L were 2.2%
and 1.4%, respectively. Transferrin, measured by an im-
munoturbidometric assay (Hitachi 917 analyzer and Roche
Diagnostics reagents) had a day-to-day variability of 2.6% and
2.4% at concentrations of 167 mg/dL and 249 mg/dL, re-
spectively.
Statistical analyses
First, we compared iron measures premenopause and
postmenopause using Wilcoxon nonparametric tests and
McNemar’s tests for categorical variables. Next, we created
stepwise linear regression models that examined change in
iron measures with menopause, adjusting for age of meno-
pause, time between premenopausal measurement and
postmenopausal measurement, race/ethnicity, and change in
waist circumference over the menopausal transition. Separate
models were created for each iron measure. Stepwise linear
regression models examined the association between changes
in iron with changes in HOMA-IR.
In additional analyses, models were constructed using
log-transformed and nontransformed measures of iron and
HOMA-IR, but the findings were similar, and we report the
findings from nontransformed models for ease of interpre-
tation. We also created models where women were catego-
rized as being iron sufficient or insufficient, and we observed
a similar pattern in results (not shown). We examined time
from menopause, which was highly correlated with age at
menopause, and observed a similar pattern of results (not
shown). Finally, we conducted analyses where change in
waist circumference was forced into the model regardless of
whether or not it met stepwise criteria for significance. The
SAS analysis system was used for all analyses (SAS Institute,
Cary, NC).
Results
Participant characteristics are illustrated in Table 1. On
average, 5 years had elapsed between the time of each
woman’s premenopausal iron measurement and postmeno-
pausal iron measurement. The mean age at natural meno-
pause was 50.9 ( – 2.9) years, and follicle-stimulating hormone
(FSH) levels were 13.1 ( – 11.8) mIU/mL in premenopause
and 74.9 ( – 50.1) mIU/mL in postmenopause. Forty-one
percent of women were Caucasian and 59% were African
Americans. Women gained a mean 2.3 ( – 6.7) kg between
their premenopausal and postmenopausal assessment and
also had a significant increase in body mass index (BMI) and
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waist circumference. Women had worsened insulin resis-
tance, as evidenced by the increases in their HOMA-IR from
premenopause to postmenopause ( p = 0.02).
In unadjusted comparisons, women had significantly lower
ferritin and higher sTfR:ferritin levels at premenopause than
at postmenopause, consistent with lower iron measures in the
premenopause. In contrast, transferrin levels were slightly
lower in postmenopause, but this result was not statistically
significant ( p = 0.055) (Table 1). In adjusted analyses, no var-
iables except for menopause status were significantly associ-
ated with iron status; postmenopause was associated with an
increase in ferritin ( p = 0.049) and a decrease in sTfR:ferritin
( p < 0.01) but not a significant change in transferrin ( p = 0.13).
In adjusted analyses, lower premenopausal iron measures
(as indicated by higher levels of premenopausal sTfR:ferritin)
and greater increases in iron measures (as indicated by greater
decreases in sTfR:ferritin) over the menopausal transition
were significantly associated with increases in HOMA-IR
from premenopause to postmenopause (Table 2). In other
words, larger increases in iron status were associated with
larger increases in HOMA-IR. Similar models substituting
transferrin and ferritin for sTfR:ferritin did not show signifi-
cant associations between these iron measures and change in
HOMA-IR (Table 2).
In sensitivity analyses, menopause was still associated with
a significant increase in ferritin when waist circumference was
forced into the model ( p = 0.046), but there was not a signifi-
cant change in sTfR:ferritin ( p = 0.15) or transferrin ( p = 0.70),
suggesting changes in iron with menopause were indepen-
dent of changes in adiposity. Similarly, the associations be-
tween lower premenopausal sTfR:ferritin levels (13.0, p = 0.03)
and changes in sTFR:ferritin (15.1, p = 0.02) were still signifi-
cant when waist circumference was forced into the models.
Addition of waist circumference to the models did not change
the association between ferritin and transferrin (premeno-
pausal levels or change in levels) with HOMA-IR (results not
shown). We also examined time since menopause and did not
find significant associations with iron measures, although
only a few years had elapsed since menopause in our sample.
Discussion
We found that from premenopause to postmenopause,
ferritin increased and sTfR:ferritin decreased, consistent with
an increase in iron stores. We also found that insulin resis-
tance and glucose increased over the menopausal transition.
Women who had the largest changes in their iron (lower
measures of iron when they were premenopausal and larger
increases in iron measures over the menopausal transition)
demonstrated the strongest associations between iron and
changes in HOMA-IR. To our knowledge, ours is the only
longitudinal study examining changes in iron measures over
the menopause and, further, the only longitudinal study ex-
amining associations with insulin resistance in a community-
based population. These findings suggest yet another path-
way through which women undergoing the menopausal
transition may be at risk for insulin resistance, in addition to
unfavorable lifestyle changes14 and the increasing ratio of
androgen:estrogen characterizing menopause.15
Previous cross-sectional studies have shown that repro-
ductive-aged women have lower iron markers than middle-
aged and elderly women.1–3 In one population-based study,
the prevalence of iron deficiency was 11% (95% confidence
interval [CI] 10%-13%) in women aged 20–49 years and 5%
(95% CI 4%-7%) in women aged 50–69 years.3 Such increases
in iron are presumably due in part to cessation of menstrual
bleeding; among premenopausal Danish women, the primary
determinant of iron measures was self-reported duration of
Table 1. Characteristics of Women at Premenopause and Postmenopause Time Points (n = 70)
Characteristic Premenopause Postmenopause
Age (years) 47.7 (3.0) 53.3 (2.9) < 0.01
Age at natural menopause (years) 50.9 (2.9)
Waist circumference (cm) 99.8 (19.1) 101.5 (18.6) < 0.01
Body mass index (kg/m2) 34.3 (9.2) 34.5 (9.6) < 0.01
Weight (kg) 89.6 (23.4) 90.0 (22.2) < 0.01
Ferritin (ng/mL) 69.5 (81.7) 128.8 (125.7) < 0.01
Change in ferritin (ng/mL) 58.2 (104.1)
Ferritin < 100 ng/mL (%) (iron insufficient) 78.6% 55.7% < 0.01
Ferritin < 15 ng/mL (%) (iron insufficient) 12.9% 0
sTfR (mg/L) 3.95 (2.69) 3.57 (1.32) 0.95
sTfR:ferritin (mean) (SD) 0.197 (0.452) 0.0598 (0.079) < 0.01
Change in sTfR:ferritin - 0.14 (0.44)
sTfr:ferritin > 1 (%) (iron insufficient) 95.7% 92.9% 0.038
sTfr:ferritin > 2 (%) (iron insufficient) 91.4% 77.1%
Transferrin (mg/dL) 278.5 (44.4) 268.3 (36.7) 0.055
Change in transferrin (mg/dL) - 10.2 (37.8)
Fasting glucose (mg/dL) 106.5 (48.3) 109.0 (51.1) 0.05
Change in fasting glucose (mg/dL) 1.2 (50.8)
HOMA-IR 4.14 (4.01) 5.21 (4.56) 0.022
Change in HOMA-IR 0.92 (3.68)
Sex hormone-binding globulin (SHBG) (nmol/L) 42.8 (21.1) 43.1 (21.6) 0.87
C-reactive protein (mg/L) 7.0 (10.9) 7.2 (7.6) 0.18
Mean (standard deviation [SD]) or percentages shown.
HOMA-IR, homeostasis model assessment of insulin resistance; sTfR, soluble transferrin receptor.
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menstrual bleeding.2 Another factor contributing to an in-
crease in iron stores included adiposity.16 In our study, ad-
justment for the increase in waist circumference diminished
the association between menopause and change in sTfR:fer-
ritin, although not between menopause and ferritin levels
alone.
Previous observations have suggested that changes in iron
measures over the menopausal transition contribute to in-
creased insulin resistance over the transition. First, among
cross-sectional1,17,18 and prospective19 studies of healthy
postmenopausal women, postmenopausal ferritin levels are
associated with increased odds of the metabolic syndrome.
The same association is not consistently observed in pre-
menopausal women,1,19 presumably because of the lower
ferritin levels among premenopausal women. Second, greater
levels of iron have been associated with increased risk of di-
abetes in nested case-control studies of healthy women
without iron overload disorders or metabolic disorders, such
as polycystic ovarian syndrome (PCOS).13,20,21 Third, among
premenopausal women with PCOS, a hyperandrogenic and
hyperinsulinemic syndrome affecting approximately 3% of
the U.S. female population,22 measures of ferritin are elevated
compared to healthy women.23 Finally, the elevated measures
of iron observed in iron overload disorders are associated
with greater diabetes risk.5
Although explanations for the associations between in-
sulin resistance and iron are speculative, inflammation as
represented by ferritin may increase insulin resistance24;
however, we found that measures of CRP, another inflam-
matory marker, did not increase over menopause. Hepcidin,
a peptide hormone produced by the liver, inhibits intestinal
iron uptake and is decreased among premenopausal women
with PCOS.23 Thus, insulin resistance may have contributed
to increased iron stores among postmenopausal women ra-
ther than vice-versa. In our healthy postmenopausal popu-
lation, however, menopause was strongly associated with
increases in iron stores, and among healthy postmenopausal
women,25 the relationships between hepcidin and iron
Table 2. Regression Coefficients and 95% Confidence Intervals in Stepwise Models
Examining Associations Between Iron (Independent Variable) and Changes
in Insulin Resistance and Glucose (Dependent Variables)
sTfR:ferritin
Model 1a Association with change in HOMA-IR
Premenopausal sTfR:ferritin 11.0 (0.017-22.0)
Change in sTfR:ferritin over menopause 13.6 (0.93-26.3)
Premenopausal sTfR:ferritin * change in sTfR:ferritin - 1.08 ( - 3.12-0.95)
Race/ethnicity - 1.81 ( - 3.70-0.079)
Intercept (menopausal status) 0.47 ( - 0.15-3.09)
Model 1b Association with change in glucose
Premenopausal sTfR:ferritin 14.1 ( - 137.1-165.3)
Change in sTfR:ferritin over menopause 132.1 ( - 42.6-306.7)
Premenopausal sTfR:ferritin * change in sTfR:ferritin 234.5 (262.6-26.4)
Race/ethnicity - 14.7 ( - 40.3-11.0)
Intercept (menopausal status) 17.06 ( - 4.75-38.88)
Ferritin
Model 2a Association with change in HOMA-IR
Premenopausal ferritin - 0.007 ( - 0.018-0.004)
Change in ferritin over menopause 0.004 ( - 0.008-0.016)
Premenopausal ferritin * change in ferritin 0.00001 ( - 0.00006-0.00008)
Race/ethnicity 22.21 (24.16-20.26)
Intercept (menopausal status) 2.48 (0.87-4.09)
Model 2b Association with change in glucose
Premenopausal ferritin 0.033 ( - 0.12-0.19)
Change in ferritin over menopause - 0.022 ( - 0.20-0.16)
Premenopausal ferritin * change in ferritin 0.0003 ( - 0.0007-0.0013)
Race/ethnicity - 22.28 ( - 50.3-5.7)
Intercept (menopausal status) 12.80 ( - 10.3-35.9)
Transferrin
Model 3a Association with change in HOMA-IR
Premenopausal transferrin 0.018 ( - 0.010-0.047)
Change in transferrin over menopause - 0.0004 ( - 0.13-0.13)
Premenopausal transferrin* change in transferrin 0.000001 ( - 0.0004-0.0004)
Race/ethnicity 22.29 (24.18-20.40)
Intercept (menopausal status) - 2.78 ( - 10.8-5.19)
Model 3b Association with change in glucose
Premenopausal transferrin 0.053 ( - 0.35-0.45)
Change in transferrin over menopause - 0.84 ( - 2.66-0.99)
Premenopausal transferrin * change in transferrin 0.003 ( - 0.003-0.009)
Race/ethnicity - 23.21 ( - 49.94-3.52)
Intercept (menopausal status) 3.73 ( - 106.4-113.8)
Significant associations are shown in bold type.
IRON CHANGES OVER MENOPAUSE 875
absorption may differ from those reported in premenopausal
women. Finally, ferritin and other iron markers have also
been associated with elevated liver function tests, particu-
larly alanine aminotransferase, which represents non-
alcoholic fatty liver disease and increased risk of insulin
resistance.17 Therefore, the relationship between iron and
insulin resistance may also be confounded or mediated by
fatty liver disease.
We found that the association between iron measures and
HOMA-IR was significant when iron was represented by
sTfR:ferritin but not by ferritin alone or transferrin alone. Two
of the nested case-control studies13,26 examined a single
measure of sTfR:ferritin and found associations with future
diabetes. Of note, we did not find large changes in the serum
sTfR levels between premenopause and postmenopause,
suggesting that the aspect of iron metabolism that may have
changed from premenopause to postmenopause was not
erythropoiesis alone.
Strengths of our report include its random selection from a
longitudinal community-based study. Limitations include its
small sample size. We used proxy measures for iron and did
not have bone marrow biopsy confirmation of iron stores.
Similarly, SWAN used proxy measures for insulin resistance,
such as HOMA-IR, as is common in large epidemiologic
studies, rather than insulin clamp measurements. The cohort
was relatively young; and it is possible that as the cohort ages
and their time since menopause increases, their iron stores
will increase even more and that iron associations with
HOMA-IR may become more pronounced. We did not mea-
sure additional markers that may have helped us delineate
the mechanisms through which iron might increase insulin
resistance, specifically hepcidin and markers of nonalcoholic
fatty liver disease. Finally, this study is observational and
cannot demonstrate cause and effect between iron and insulin
resistance.
In conclusion, we observed changes in iron markers con-
sistent with increased iron stores over the menopause. In
addition, we observed small increases in insulin resistance
over the menopause and associations between iron measures
and insulin resistance. Women who had the largest changes in
iron measures, that is, lower iron in the premenopause and
larger increases over the transition, had the strongest associ-
ations between changes in iron and changes in HOMA-IR.
Given the increasing number of menopausal women and the
fact that iron is a modifiable risk factor, the contribution of
iron to insulin resistance should be replicated in larger studies
before and after consideration of additional confounders,
particularly liver metabolism, adipocytokines, and oxidative
stress.
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